spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  ELOCTA 

 HSMN NewsFeed - 19 Jun 2024
European Commission grants Sobi(R) Marketing Authorisation for ALTUVOCT(TM) for treatment of haemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Apr 2024
Sobi(R) Receives Positive CHMP Opinion Recommending Approval of Efanesoctocog Alfa for Once-Weekly Treatment of Haemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Feb 2023
FDA approves once-weekly efanesoctocog alfa, a new class of high-sustained factor VIII therapy for haemophilia A: Swedish Orphan Biovitrum AB
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Oct 2017
Sobi: Alprolix(R) Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia B
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Aug 2017
Rhythm Expands Executive Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 May 2017
Swedish Orphan Biovitrum AB - Elocta(R) Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Nov 2015
Sobi and Biogen’s ELOCTA(R) (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Aug 2014
Health Canada Approves Eloctate(TM), the First Therapy to Extend the Interval Between Prophylactic Infusions in Hemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Jan 2014
Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
Biopharmaceuticals Licensing
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.